Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis
- PMID: 36244178
- DOI: 10.1016/j.leukres.2022.106929
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis
Conflict of interest statement
Declaration of Competing Interest A.C.K. has received advisory/consulting fees from: Astellas and Blueprint Medicines. E.M.S. has received advisory/consulting fees from: Foghorn Therapeutics; Blueprint Medicines; Gilead Sciences; Abbvie; Janssen Pharmaceuticals; Genentech; Jazz Pharmaceuticals; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Astellas; Novartis; Agios Pharmaceuticals; Syros Pharmaceuticals, Inc; Syndax Pharmaceuticals. Remaining authors have nothing to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical